Lynavoy (Linerixibat)

Where it stands

Lynavoy (linerixibat) is authorised in the EU. The European Commission decision of 22 October 2026 granted the marketing authorisation to GlaxoSmithKline Trading Services Limited. The CHMP positive opinion came on 23 July 2026. The approved indication is the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).

The records also show a US approval. The FDA approved Lynavoy on 17 March 2026 as a new molecular entity (NDA220295, tablet formulation). The US entry names Intercept, while the EU authorisation is held by GlaxoSmithKline Trading Services Limited. The records do not explain how the two companies relate to each other or to the product, so no conclusion should be drawn about that.

The FDA approval came about seven months before the EC decision, so the US decision preceded the EU one. The records give no detail on the US label, so they do not show whether the US and EU indications match.

Regulatory pathway and designations

The EU product carries an Orphan designation and an Additional monitoring flag. The record shows two steps: the CHMP positive opinion on 23 July 2026 and the EC decision on 22 October 2026. This is the standard centralised route, in which the CHMP opinion is followed by a legally binding Commission decision valid across the EU. The nominal target for the Commission decision is 67 days after the opinion. The interval here was longer, about 91 days, and the records give no reason for it.

Orphan status in the EU is tied to the rare-disease criteria and can bring incentives such as market exclusivity. The records confirm the designation is attached to this product at the time of approval. They do not give the designation date, the sponsor of the designation, the orphan maintenance assessment or any exclusivity period, so those should be checked in the Union Register and the EPAR once published.

The records do not cover the review type (for example, standard or accelerated assessment) or whether the authorisation is full, conditional or under exceptional circumstances. The EU record shows it only as 'Authorised'.

Safety and pharmacovigilance

The only safety-related information in the records is the Additional monitoring status. This means the product appears on the EU list of medicines under additional monitoring, which is marked with a black inverted triangle in the product information. The product information also includes a standard statement encouraging healthcare professionals and patients to report suspected adverse reactions. The status does not in itself indicate a specific safety problem.

The records contain no adverse-event data, contraindications, warnings, risk management plan content, additional risk minimisation measures or post-authorisation safety study obligations. Professionals should consult the SmPC, the EPAR and the risk management plan summary for these once available.

What to watch

Publication of the EPAR and the final EU product information is the next step. They would clarify the benefit-risk basis, any conditions or obligations attached to the authorisation, and the orphan assessment. Comparing the EU and US labels, including indication wording and safety sections, would show whether the two regions diverge.

Next, watch for national launch and reimbursement steps, which the records do not cover. The same applies to post-authorisation commitments and any early safety communications arising from the additional monitoring period. The records contain no information on any of these, and nothing should be inferred about timing or outcomes.